|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.73 AUD | -1.33% |
|
+2.62% | -16.98% |
| May. 09 | Neuren Pharmaceuticals Partner Acadia Pharmaceuticals Posts US DAYBUE Sales of $75.9 Million | MT |
| Apr. 24 | Neuren Pharmaceuticals Posts AU$243 Million Cash, Short-Term Investments | MT |
Neuren Pharmaceuticals Limited reported earnings results for the half year ended June 30, 2022. For the half year, the company reported revenue was AUD 0.283 million compared to AUD 0.234 million a year ago. Net loss was AUD 7.05 million compared to AUD 7.96 million a year ago.
Basic loss per share from continuing operations was AUD 0.056 compared to AUD 0.07 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -16.98% | 1.79B | |
| +34.35% | 705B | |
| +31.07% | 583B | |
| -3.49% | 364B | |
| +20.15% | 332B | |
| +6.19% | 291B | |
| +15.45% | 238B | |
| -3.23% | 210B | |
| +10.36% | 209B | |
| +9.21% | 169B |
NEUREN PHARMACEUTICALS LIMITED 
